Pleas	type a plus sign (+) inside this box ->	+
-------	---	---

PTO/SPIORA /40 OC

Patent and Trade

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of informati

1 10/00/00/ (10-30)	
oproved for use through 10/31/99. OMB 0654-0031	
mark Office: U.S. DEPARTMENT OF COMMERCE	ı
on unless it contains a valid OMB control number.	


Substitut 1	or form 1449A	VPTO		Стр	lete if Known
INFO	RMATI	ON DIS	SCLOSURE	Application Number	Not yet Assigned
				Filing Date	January 29, 2004
SIAI	FMFN	IRAY	PPLICANT.	First Named Inventor	Rosana Kapeller-Libermann, et al.
			•	Group Art Unit	N/A
	(use as m	any sheets as	s necessary)	Examiner Name	N/A
Sheet	1	of	1	Attorney Docket Number	MPI99-193CN2M

				U.S. PATENT DOCUME	NTS	
Examiner Initials*			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Wh re Relevant Passages or Relevant Figures Appear	
1/2	AA	US 4,185,156		Umezawa et al.	01/22/1980	Column 1, Line 1 Column 2, Line 31
			_			
				·		
					-	

				FORE	IGN PATENT DOCUM	MENTS		
Examiner Initials*	Cite No. ¹	Fore Office ³	ign Patent Do	ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

•	0		
Examiner Signature	MU	Date Considered	8/25/08
		•	

¹Unique citation design number. ²S attached Kinds of U.S. Patent Docum nts. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japan s patent documents, th indication of the year of th reign of the Emp ror must preced the serial number of the pat int document. SKind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English languag Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box>	+
--	---

PTO/SB/08B (10-96)

Approved for us through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449B/PTO			Complete if Known		
INFO	RMATION	DISCL	OSURE	Application Number	Not yet Assigned	
-				Filing Date	January 29, 2004	
SIA	rement b	Y APPL	ICANT -	First Named Inventor	Rosana Kapeller-Libermann, et al.	
		•		Group Art Unit · ·	N/A	
	(use as many s	heets as neces:	sary)	Examiner Name	N/A	
Sheet	1	of	2	Attorney Docket Number	MPI99-193CN2M	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item	Т
Examiner nitials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	;
	CA	BLAST searches in DBEST, NRN, NRP and PATENT Databases	T
	СВ	Annotation on GenBank Accession No. U49278	İ
	cċ	Anderson, "Human Gene Therapy," Nature, April 30, 1998, Vol. 392 Supp., pp. 25-30	\mid
$\langle \mathcal{U} \rangle$			
725	CD	Beattie et al., Abstract, "The Use of Multiple Pin Peptide Synthesis in an Analysis of the Continuous Epitopes Recognized by Various Anti-(recombinant bovine growth hormone) Sera," European Journal of Biochemistry, November 15, 1992, pp. 59-66, Vol. 210, No. 1	
	CE	Bloecker et al., Nucleotide and Protein Databases, Direct Submission, EBI UK Accession No. Q9NP17	
RS	CF	Cadel et al, "Aminopeptidase B from the Rat Testis is a Bifunctional Enzyme Structurally Related to Leukotriene-A ₄ Hydrolase," <i>Proc. Natl. Acad. Sci. USA</i> , 1997, pp 2963-2968, Vol. 94	ĺ
	CG	Dedinsky et al., "Antigenic Determinants of Cytochrome P450 Superfamily and Their Classification," 8 th Russia Cytochrome P450 Int. Conf., 1994, Abstract No. 119832	
	СН	Draoui, et al., "Expression and Retinoid Modulation N-argine Dibasic Convertase and an Aminopeptidase-B in Human Neuroblastoma Cell Lines," <i>Journal of Neuro-Oncol</i> ogy, 1997, pp. 99-106, Vol. 31, No. 12	
	CI	Foulon, et al., "Aminopeptidase B (EC 3.4.11.6)," International Journal of Biochemistry & Cell Biology, July 1999, pp. 747-750, Vol. 31, No. 7	
Z5	ယ	Fukasawa, et al, "Molecular Cloning and Expression of Rat Liver Aminopeptidase B," Journal of Biological Chemistry, November 29, 1998, pp. 30731-30735, Vol. 271, No. 48	

^{*}EXAMINER: Initial if refer nce considered, whether or not citation is in conformance with MPEP 609. Draw lin through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is stimat d to take 2.0 hours to complet . Tim will vary depending upon the n eds of th individual case. Any comments on th amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OF COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

4

¹Unique citation design numb r. ²Applicant is to place a check mark here is English language Translation is attached.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons gre required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 144	9B/PTO		Сотр	lete if Known
INFC	RMAT	ION DIS	SCLOSURE	Application Number	Not yet Assigned
_				Filing Date	January 29, 2004
SIA	IFMFL	NIBYA	PPLICANT	First Named Inventor	Rosana Kapeller-Libermann, et al.
				Group Art Unit	N/A
(use as many sheets as necessary)				Examiner Name	N/A
Sheet	2	of	2	Attorney Docket Number	MPI99-193CN2M

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city	Т
Initials*	No.1	and-or country where published.	2
	CK	Kristensen, "Human Aminopeptidase B cDNA Cloning," Nucleotide and Protein Sequences, Direct Submission Oct. 2000, EBI UK Accession No. Q9H4A4	
	CL	NCI-CGAP, Nucleotide and Protein Sequences, Direct Submission, EBI UK Accession No. A1582355	
	СМ	NCI-CGAP, Nucleotide and Protein Sequences, Direct Submission, EBI UK Accession No. AW167220	
25	CN	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 491-495	
	СО	Piesse et al., "Human Aminopeptidase B on Chromosome 1q32.2:cDNA, Genomic Structure and Expression," Direct Submission May 1999, EBI UK Accession No. Q9H1D4	
	СР	Rudinger, "Characteristics of the Amino Acids and Components of a Peptide Hormone Sequence," Peptide Hormones, June 1976, pp 5-7/	
PS	CQ	Sancho, et al., "Role of UEV-1, an Inactive Variant of the E2 Ubiquitin-Conjugating Enzymes, in In Vitro Differentiation and Cell Cycle Behavior of HT-29-M6 Intestinal Mucosecretory Cells," <i>Molecular and Cellular Biology</i> , Jan. 1998, pp. 576-589, Vol. 18, No. 1	
	CR	Sugano, et al., Nucleotide and Protein Sequences, Direct Submission, EBI UK Accession No. AK026644	
28	CS	VERMA, et al., "Gene Therapy – Promises, Problems and Prospects," <i>Nature</i> , September 18, 1997, Vol. 389, pp. 239-242	
')			
Examiner Signature		Date Considered 8/25/05	<u></u>

^{*}EXAMINER: Initial if r ference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to tak 2.0 hours to complete. Time will vary depending upon the n eds of the individual case. Any comments on the amount of time you are r quired to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attach d.